Medical Advocates
Tipranavir (Aptivus)
Conference Citations Archives

 3rd IAS Conference
 12th CROI
6th International Wkshop of Clinical HIV
 44th ICAAC
 XV International AIDS Conference
 2nd IAS Conference on HIV and Pathogenesis
 XII International HIV Drug Resistance Workshop
9th CROI
 41 ICAAC
XIV International AIDS Conference
 1st AS Conference on HIV and Pathogenesis
 		  
Tipranavir Conference Main Page New/Noteworthy Home Page      

Last Update:  August 27, 2007 
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
3rd IAS Conference on HIV and Pathogenesis
 
  • POSTER
         Tipranavir/ritonavir Demonstrates Superior Immunological Response  to Comparator
    Protease Inhibitors in a PI-Experienced Population with Advanced Disease
         C Hicks, B Grinstzejn. P Cahn, et al
    PDF Poster
  • POSTER
         Tipranavir/ritonavir Demonstrates Superior Treatment Response to Lopinavir,
    Amprenavir, and Saquinavir in PI-Experienced Patients from the TPV RESIST-1
    and RESIST-2 Disease
    A Lazarrin, G Mukwaya., N Clumek, et al 
     PDF Poster
  • Binding energetics analysis shows a unique response of tipranavir to HIV-1 protease mutations
    associated with drug resistance
    Muzammil S., Kang L.-W., Armstrong A.A, et al
    Abstract
  • A Long-Term Open-Label Rollover Trial Assessing the Safety and Tolerability of Combination
    Tipranavir and Ritonavir (TPV/r) Use in HIV-1–Infected Patients
    Pierone G., Drulak M., Arasteh K., et al
    Abstract
  • The Pharmacokinetics (PK) of Single-dose and Steady-state Tipranavir/Ritonavir (TPV/r) 500
    mg/200 mg in Subjects with Mild or Moderat.e Hepatic Impairment
    Cooper C., van Heeswijk R., Bilodeau M., et al
    Abstract
  • Tipranavir/ritonavir (TPV/r) 500 mg/200 mg BID drives week 24 viral load (VL) below 400
    copies/mL when combined with a second active drug (T-20) in protease inhibitor experienced
    HIV+ patients.
    Valdez H., McCallister S., Kohlbrenner V., Mayers D.
    Abstract
  • Is predicted susceptibility to tipranavir/ritonavir (TPV/r) in treatment-experienced patients
    better than for other PI-boosted regimens ?
    Boulmé R., Gonzalez D., Struck D., et al
    Abstract
  • An Open-Label Steady State Investigation of the Pharmacokinetics (PK) of Tipranavir (TPV)
    and Ritonavir (RTV) and their Effects on Cytochrome P-450 (3A4) Activity in Normal Healthy
    Volunteers
    Nwando O., Themba B.
    Abstract
    •
    12th Conference on Retroviruses and
    Opportunistic Infections
    6th International Workshop on Clinical  Pharmacology
    of HIV Therapy
    • POSTER
      Evaluation of the bioavailability of Tipranavir/Ritonavir (TPV/r) 500 mg/200 mg oral
      solution (OS): Comparison to TPV capsules, and the influence of food intake in
      healthy volunteers
             J .Sabo, et al
      PDF Poste      r
    • POSTER
      The pharmacokinetics (PK) of single-dose and steady-state Tipranavir/Ritonavir
      (TPV/r) 500 mg/200 mg in subjects with mild or moderate hepatic impairment
       C Cooper, et al
       PDF Poster
    44th ICAAC
     
    XV International AIDS Conference
     
    2nd IAS Conference on HIV and Pathogenesis
     
    XII International HIV Drug Resistance Workshop
     
    XIV International  AIDS Conference 
     
    9th Conference on Retroviruses and Opportunistic Infections
     
    • POSTER
             Resistance to Tipranavir is Uncommon in a Randomized Trial of Tipranavir/Ritonavir
      (TPV/RTV) in Multiple PI-Failure Patients (BI 1182.2) 
      R. Schwartz , P. Kazanjian, L. Slater, et al.
      PDF Poster     Abstract
    41st ICAAC   
     
    1st IAS Conference on HIV and Pathogenesis
     

    Tipranavir Conference Main Page New/Noteworthy Home Page      

    Tipranavir Conference Citations Archives